J&J unit submits blood cancer drug for EU approval

10/31/2013 | Pharmaceutical Business Review Online

A marketing authorization application was filed by Janssen-Cilag, a Johnson & Johnson unit, with the European Medicines Agency for ibrutinib, a once-daily drug to treat two kinds of blood cancer. The drug is intended for adults with relapsed or refractory mantle cell lymphoma and for those with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY